Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021 Feb 08;: Authors: Yu A, Huang E, Abe M, An K, Park SK, Park C Abstract INTRODUCTION: : Mutation-targeting and immuno-oncology drugs are revolutionizing the treatment of advanced non-small cell lung cancer (NSCLC). Cost-effectiveness analyses (CEA) of these drugs have been conducted using various analytical methods and cost-effectiveness thresholds. This systematic review provides a comprehensive summary of the available evidence. AREA COVERED: : PubMed, Embase, and Cochrane Library were used to select for CEA of targeted therapies for NSCLC in the U.S. published between 2008 and 2020. Among the 28 included studies, a majority were published from 2017-2020 (n=18) and more than half targeted non-squamous NSCLC (n=15). The most frequently evaluated therapy was pembrolizumab (n=11), followed by bevacizumab (n=8) and erlotinib (n=4). The cost-effectiveness of pembrolizumab varied by the programmed death-ligand 1 tumor proportion score and the cost-effectiveness threshold used in each study. After 2009, all included studies applied $100,000 or more thresholds. Thresholds of studies supported by industry (median=$150,000) were more distributed than those of studies supported by nonprofits (median=$100,000). EXPERT COMMENTARY: : Medicati...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research